Skip to main content

Portage Biotech Inc. (PRTG)

New York Stock Exchange Healthcare BiotechnologyView data quality →
38.1Poor

ValueMarkers Composite Index

Top 4%#42,887 of 44,707
Overvalued

2934% above intrinsic value ($0)

UndervaluedFair ValueOvervalued
Piotroski
2/9
Weak
Beneish
-
Altman
-161.74
Distress
DCF Value
$0
Overvalued
ROIC
-116.3%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Portage Biotech Inc. (PRTG) — VMCI valuation read

The headline on Portage Biotech Inc. (PRTG) is a 38/100 VMCI score, set against a Healthcare sector median of 50. That 12-point below-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value drag is in the data.

PRTG insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** PRTG trades at 19.0x earnings, 6% above the Healthcare median of 18.0x sets the value side. ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of -2.1x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on PRTG.

PRTG fell 1.0% over the trailing 7 days, with a -11.9% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in PRTG’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.